Clene Prices $7M Offering of 1M Shares at $7 Per Share for NDA Filing
Clene has priced a registered direct offering of 1,000,000 common shares at $7.00 each, generating approximately $7 million in gross proceeds. Net proceeds will fund CNM-Au8’s New Drug Application prep, ongoing expanded access protocols, confirmatory Phase 3 trial, manufacturing expansion, potential commercialization and early-stage R&D.
1. Registered Direct Offering Details
Clene launched an underwritten registered direct offering of 1,000,000 common shares at $7.00 per share to a single investor, generating approximately $7 million in gross proceeds. The offering is expected to close on or about May 6, 2026, subject to customary closing conditions, with Canaccord Genuity acting as sole bookrunner.
2. Use of Net Proceeds
The company expects to use net proceeds alongside existing cash primarily for general corporate purposes, including preparation and filing of its New Drug Application for CNM-Au8, support of ongoing expanded access protocols and the confirmatory Phase 3 clinical trial, expansion of manufacturing capacity, potential commercialization activities and additional early-stage R&D.
3. Upcoming May Conference Presentations
Clene will present virtually at the Emerging Growth Conference on May 6, 2026 at 3:25 p.m. ET, then hold one-on-one meetings at the D. Boral Capital Global Conference on May 7 at The Plaza Hotel in New York City, offering investors updates on its clinical-stage pipeline and development strategy.